Georgia Medical Cannabis Program — Eligibility, Registration & Dispensaries

Executive Summary

Georgia operates one of the most restrictive medical cannabis programs in the United States, permitting only low-THC cannabis oil possession for a narrow list of qualifying conditions. Established through Haleigh's Hope Act in 2015 and expanded by the Georgia Access to Medical Cannabis Act in 2019, the program allows registered patients to possess up to 20 fluid ounces of cannabis oil containing no more than 5% THC. Unlike most medical cannabis states, Georgia prohibited in-state cultivation and sales until 2019, forcing patients to obtain medicine from out-of-state sources despite federal prohibition making transport illegal. The 2019 legislation authorized up to six licensed production facilities, but regulatory delays, legal challenges, and implementation obstacles meant the first dispensaries did not open until late 2023. As of May 2026, Georgia's program serves approximately 28,000 registered patients across 18 qualifying conditions, with recent legislative expansions adding new conditions and attempting to address access barriers that have plagued the program since inception. The state's approach reflects the tension between conservative legislative caution and patient advocacy pressure in the Deep South.

Why This Matters

Georgia's medical cannabis program affects over 28,000 registered patients who rely on low-THC oil for conditions ranging from intractable seizures to terminal cancer, yet access remains severely constrained by limited dispensary infrastructure and restrictive qualifying conditions. The program's restrictive framework has significant implications for multiple stakeholder groups. Patients with qualifying conditions face substantial barriers to access, including limited dispensary locations concentrated in metro Atlanta, high product costs averaging $150-200 per ounce of oil, and a cumbersome registration process requiring specialized physician certification. Many Georgia patients continue purchasing cannabis illegally or traveling to neighboring states with more permissive programs, exposing themselves to criminal liability. For the state's healthcare system, the program represents a cautious experiment in medical cannabis policy. Georgia physicians must complete specialized training and register with the state to certify patients, creating additional administrative burden. The Georgia Composite Medical Board and Department of Public Health oversee physician participation and patient registration, managing a database that tracks all participants. The economic impact remains modest compared to robust medical programs in other states. The six licensed production companies invested an estimated $50-80 million combined in cultivation and processing facilities, creating approximately 400-600 direct jobs. However, the limited patient population and product restrictions constrain market growth. Industry analysts estimate Georgia's medical cannabis market generated $15-20 million in sales during 2025, a fraction of the revenue seen in states with comprehensive programs. Law enforcement agencies navigate the program's complexities, distinguishing between legal registered patients carrying proper documentation and illegal possession. The 20-ounce possession limit and low-THC requirement create enforcement challenges, as field testing cannot reliably distinguish compliant oil from illegal cannabis products.

Background and History: From Haleigh's Hope to Limited Access

Georgia's medical cannabis program evolved through three major legislative phases spanning 2015-2019, driven by parent advocates for children with severe epilepsy and constrained by conservative legislative resistance to broader legalization.

The Haleigh's Hope Act (2015): Possession Without Access

Georgia's medical cannabis journey began with House Bill 1, known as Haleigh's Hope Act, signed into law by Governor Nathan Deal on April 16, 2015. Named after Haleigh Cox, a young Georgia girl whose family advocated for cannabis oil access to treat her severe seizures, the legislation represented a narrow compromise between patient advocates and conservative lawmakers wary of broader legalization. The 2015 law created an affirmative defense for possession of low-THC cannabis oil, defined as containing no more than 5% THC and at least an equal amount of CBD. The legislation established eight qualifying conditions: cancer, amyotrophic lateral sclerosis (ALS), seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's disease, and sickle cell disease. Patients could possess up to 20 fluid ounces of compliant oil if registered with the state and certified by a physician. However, the law contained a critical flaw: it legalized possession but not cultivation, production, or sale within Georgia. Patients had no legal mechanism to obtain the medicine they were permitted to possess. The legislation's sponsors acknowledged this gap but argued the law provided protection for families already obtaining cannabis oil from other states, despite federal law prohibiting interstate cannabis transport. Between 2015 and 2019, Georgia patients existed in legal limbo. Approximately 3,000-4,000 patients registered with the state during this period, but all faced the impossible choice of going without medicine or breaking federal law to obtain it. Parent advocates, particularly those with children experiencing severe epilepsy, traveled to Colorado, California, and other states with legal cannabis programs, purchasing oil and transporting it back to Georgia despite the risk of federal prosecution.

Failed Expansion Attempts (2016-2018)

Following the 2015 law's passage, patient advocates and some legislators pushed for in-state production authorization. Multiple bills introduced between 2016 and 2018 sought to establish a regulated cultivation and dispensing system, but all failed to gain sufficient support in the Republican-controlled General Assembly. House Bill 722 in 2017 would have authorized up to six production licenses and established a regulatory framework overseen by the Georgia Department of Public Health. The bill passed the House but died in the Senate, where conservative members expressed concerns about federal prohibition and potential conflicts with law enforcement. Senator Renee Unterman, a vocal opponent, argued that any in-state production would violate the federal Controlled Substances Act and potentially jeopardize federal funding for state programs. During this period, the patient registry continued growing, reaching approximately 6,500 registered individuals by early 2019. Advocacy organizations including Georgia's Hope and Peachtree NORML organized lobbying efforts, bringing patients and families to the State Capitol to testify about their experiences. These personal stories, particularly from parents of children with Dravet syndrome and other severe epilepsies, gradually shifted legislative opinion.

The Georgia Access to Medical Cannabis Act (2019)

The breakthrough came with House Bill 324, the Georgia Access to Medical Cannabis Act, signed by Governor Brian Kemp on April 17, 2019. This comprehensive legislation finally authorized in-state production and established the regulatory framework that governs the program today. The 2019 law authorized the Georgia Access to Medical Cannabis Commission to issue up to six Class 1 production licenses and up to two Class 2 licenses. Class 1 licensees could cultivate cannabis, manufacture low-THC oil, and operate up to five dispensaries each. Class 2 licensees could manufacture oil from raw material purchased from Class 1 producers and operate dispensaries. The legislation expanded qualifying conditions to include Tourette's syndrome, autism spectrum disorder, epidermolysis bullosa, Alzheimer's disease, AIDS, and peripheral neuropathy, bringing the total to 16 conditions. The law established strict operational requirements. Production facilities must operate under pharmaceutical-grade security and quality control standards. All products must undergo third-party laboratory testing for potency, contaminants, and pesticides. Dispensaries cannot operate within 1,000 feet of schools, childcare facilities, or churches. The legislation prohibited smoking or vaporizing cannabis, limiting consumption to oils, capsules, topicals, and other non-inhalable forms. Critically, the law maintained the 5% THC limit and prohibited whole-plant cannabis sales. This restriction distinguished Georgia from most medical cannabis states, which permit higher-THC products and various consumption methods. Advocates argued the limitation unnecessarily restricted patient choice, but legislative supporters insisted the cap was necessary to maintain political support.

Implementation Delays and Legal Challenges (2019-2023)

Despite the 2019 law's passage, implementation proved extraordinarily slow. The Georgia Access to Medical Cannabis Commission, appointed by Governor Kemp and legislative leaders, did not issue its first production licenses until July 2021—more than two years after the law's enactment. The commission received 69 applications for the six Class 1 licenses, reflecting significant industry interest despite the program's limitations. The evaluation process involved detailed reviews of applicants' financial capacity, operational plans, security protocols, and community support. On July 23, 2021, the commission announced the six winning applicants: Botanical Sciences LLC, Trulieve Georgia LLC, Natures GA LLC, Theratrue Georgia LLC, FFD GA Holdings LLC, and Treevana Remedy Inc. Unsuccessful applicants immediately filed legal challenges. In August 2021, three rejected applicants sued the commission in Fulton County Superior Court, alleging the selection process violated Georgia's Open Meetings Act and involved conflicts of interest. The lawsuit claimed commission members had undisclosed relationships with winning applicants and conducted deliberations in closed sessions that should have been public. The litigation delayed the program for an additional 18 months. In February 2023, the Georgia Supreme Court ruled in Georgia Access to Medical Cannabis Commission v. Greenhouse Wellness LLC that the commission had followed proper procedures and the selection process was valid. This decision cleared the way for licensed producers to begin construction and cultivation. The first dispensary opened in Marietta on November 3, 2023, operated by Botanical Sciences. By the end of 2023, three of the six licensees had opened a combined eight dispensary locations. As of May 2026, all six production companies operate at least one dispensary, with 22 total locations across the state, concentrated in the Atlanta metropolitan area, Augusta, Savannah, and Macon.

Recent Expansions (2024-2026)

The General Assembly passed additional expansions in 2024 and 2026. House Bill 196, enacted in April 2024, added post-traumatic stress disorder (PTSD) and intractable pain to the qualifying conditions list, bringing the total to 18 conditions. The legislation also streamlined the physician certification process, allowing physicians to certify patients through telemedicine appointments rather than requiring in-person visits. The May 2026 expansion, referenced in recent news coverage, added opioid use disorder and chronic pain to the qualifying conditions and increased the number of permitted Class 1 licenses from six to eight. Advocates celebrated the expansion as progress toward broader access, though many continued pushing for higher THC limits and additional consumption methods.

Key Players in Georgia's Medical Cannabis Program

Georgia Access to Medical Cannabis Commission

The seven-member commission oversees all licensing, regulatory compliance, and enforcement activities. Governor Brian Kemp appoints four members, while the Lieutenant Governor and House Speaker each appoint one member, and the State Board of Pharmacy appoints one member. The commission operates within the Georgia Department of Public Health but maintains independent decision-making authority over licensing and regulatory matters. The commission's responsibilities include evaluating license applications, conducting compliance inspections, investigating complaints, and recommending regulatory changes to the General Assembly. As of 2026, the commission employs approximately 15 full-time staff members who conduct facility inspections, review testing results, and manage the patient registry database.

Licensed Production Companies

The six original Class 1 licensees represent a mix of multi-state operators and Georgia-based companies. Trulieve Georgia LLC, a subsidiary of Florida-based Trulieve Cannabis Corp, operates five dispensaries and represents the largest footprint among licensees. The company invested approximately $15 million in a 100,000-square-foot cultivation and processing facility in Jackson County. Botanical Sciences LLC, a Georgia-owned company backed by Atlanta-area investors, opened the state's first dispensary and operates four locations as of May 2026. The company emphasizes its local ownership and community ties, contrasting itself with multi-state operator competitors. The other licensees—Natures GA LLC, Theratrue Georgia LLC, FFD GA Holdings LLC, and Treevana Remedy Inc.—each operate between two and four dispensaries. Industry sources estimate the six companies collectively invested $60-80 million in facilities and infrastructure between 2021 and 2025.

Patient Advocacy Organizations

Georgia's Hope, founded by parents of children with severe epilepsy, played a central role in passing both the 2015 and 2019 legislation. The organization continues advocating for program expansion, including higher THC limits, additional qualifying conditions, and more dispensary licenses. Executive Director Shannon Cloud testified before the General Assembly multiple times between 2015 and 2026, sharing stories of Georgia families forced to relocate to other states or risk federal prosecution to access medicine. Peachtree NORML, the Georgia chapter of the National Organization for the Reform of Marijuana Laws, advocates for broader legalization beyond the medical program. The organization supported the medical cannabis legislation as an incremental step while continuing to push for adult-use legalization and criminal justice reforms.

Medical Community

The Georgia Composite Medical Board regulates physician participation in the program. As of May 2026, approximately 450 physicians have completed the required training and registered to certify patients. The board requires physicians to complete a four-hour continuing medical education course covering cannabis pharmacology, qualifying conditions, and program regulations before certifying patients. Some medical organizations initially opposed the program. The Medical Association of Georgia expressed concerns in 2015 about recommending a substance that remains federally illegal and lacks FDA approval. However, the organization's position softened over time, and by 2019 it took a neutral stance, emphasizing physician discretion and patient autonomy.

Law Enforcement

The Georgia Sheriffs' Association and Georgia Association of Chiefs of Police initially opposed the 2015 and 2019 legislation, citing concerns about impaired driving, federal law conflicts, and enforcement challenges. However, both organizations ultimately took neutral positions, acknowledging the narrow scope of the program and the registry system that allows officers to verify patient status. The Georgia Bureau of Investigation maintains the Low THC Oil Registry, which law enforcement can access to verify whether an individual possesses valid patient registration. Officers who encounter individuals possessing cannabis oil can check the registry in real-time through their patrol car computers.

Legal and Regulatory Framework

Georgia's medical cannabis program operates under O.C.G.A. § 16-12-190 through § 16-12-212, establishing one of the nation's most restrictive regulatory frameworks with strict THC limits, limited qualifying conditions, and pharmaceutical-grade production requirements.

Statutory Foundation

The program's legal foundation rests on two primary statutes. O.C.G.A. § 16-12-191, enacted through the 2015 Haleigh's Hope Act, created the affirmative defense for possession of low-THC oil and established the initial qualifying conditions. O.C.G.A. § 16-12-200 through § 16-12-212, enacted through the 2019 Georgia Access to Medical Cannabis Act, established the licensing system, production regulations, and dispensary requirements. The statutes define low-THC oil as "an oil that contains an amount of cannabidiol and not more than 5 percent by weight of tetrahydrocannabinol, including precursors thereof or a combination of tetrahydrocannabinol and tetrahydrocannabinol acid, that has been extracted from marijuana or synthesized in a laboratory." This definition excludes whole-plant cannabis, higher-THC products, and smokable forms.

Qualifying Conditions

As of May 2026, Georgia recognizes 18 qualifying medical conditions:

• Cancer (end-stage or related to treatment)
• Amyotrophic lateral sclerosis (ALS)
• Seizure disorders related to diagnosis of epilepsy or trauma-related head injuries
• Multiple sclerosis
• Crohn's disease
• Mitochondrial disease
• Parkinson's disease
• Sickle cell disease
• Tourette's syndrome
• Autism spectrum disorder (severe)
• Epidermolysis bullosa
• Alzheimer's disease
• AIDS
• Peripheral neuropathy
• Post-traumatic stress disorder (PTSD)
• Intractable pain
• Opioid use disorder
• Chronic pain

Patients must obtain certification from a physician registered with the Georgia Composite Medical Board. The physician must have a bona fide physician-patient relationship and determine that the patient has a qualifying condition for which the potential benefits of low-THC oil outweigh the risks.

Patient Registration and Possession Limits

Patients must register with the Low THC Oil Registry maintained by the Georgia Department of Public Health. Registration requires submission of the physician certification, proof of Georgia residency, and a $25 application fee. The department issues registry identification cards valid for two years. Registered patients may possess up to 20 fluid ounces of low-THC oil. The statute does not specify whether this limit applies to total possession at any given time or to a monthly purchase limit, creating some ambiguity in practice. Patients may designate caregivers who can possess and transport oil on their behalf, which is particularly important for pediatric patients and individuals with mobility limitations.

Production and Dispensary Regulations

Class 1 production licensees must meet extensive operational requirements detailed in Georgia Comp. R. & Regs. 111-14. Cultivation facilities must implement pharmaceutical-grade security systems including 24-hour video surveillance, restricted access zones, and alarm systems monitored by licensed security companies. All cultivation must occur indoors in climate-controlled environments. Processing and manufacturing must follow Good Manufacturing Practices as defined by the FDA. All products must undergo testing by independent, ISO-accredited laboratories for potency, residual solvents, pesticides, heavy metals, and microbial contaminants. Products failing testing cannot be sold and must be destroyed under commission supervision. Dispensaries must maintain detailed inventory tracking from seed to sale using the commission-mandated software system. All transactions must be recorded electronically, and dispensaries must submit monthly reports detailing sales volumes, product types, and patient counts. Dispensaries cannot advertise through broadcast media, billboards, or print publications with significant youth audiences.

Federal Law Conflicts

Georgia's program operates in direct conflict with federal law. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. The Rohrabacher-Farr Amendment, renewed annually in federal appropriations bills since 2014, prohibits the Department of Justice from using federal funds to interfere with state medical cannabis programs, providing practical protection despite the theoretical federal prohibition. However, Georgia patients and licensees remain technically vulnerable to federal prosecution. Federal law prohibits cannabis possession, cultivation, and distribution regardless of state law authorization. While the Biden administration maintained a policy of non-interference with state-compliant medical cannabis operations, this policy could change under future administrations. The federal prohibition also creates banking challenges. Most federally-insured financial institutions refuse to serve cannabis businesses due to concerns about money laundering violations under 18 U.S.C. § 1956. Georgia dispensaries operate primarily on a cash basis, creating security risks and operational complications.

State-by-State Context: Georgia in the Southeast

Georgia's restrictive medical cannabis program stands in stark contrast to more permissive frameworks in neighboring states, creating cross-border patient migration and highlighting regional policy divergence.

Georgia: Limited Low-THC Program

Georgia permits only low-THC oil (maximum 5% THC) for 18 qualifying conditions. Patients may possess up to 20 fluid ounces. Six licensed production companies operate 22 dispensaries statewide as of May 2026. Approximately 28,000 registered patients. No home cultivation permitted. No smokable products allowed.

Florida: Comprehensive Medical Program

Florida operates one of the nation's largest medical cannabis programs, with over 800,000 registered patients as of 2026. The state permits full-strength THC products including flower, concentrates, edibles, and topicals. Florida recognizes a broad list of qualifying conditions and allows physicians significant discretion in certifying patients. More than 20 licensed Medical Marijuana Treatment Centers operate over 400 dispensaries statewide. The program generates over $2 billion in annual sales. Many Georgia patients travel to Florida to establish temporary residency and access the more permissive program.

Alabama: Emerging Medical Program

Alabama enacted the Darren Wesley 'Ato' Hall Compassion Act in May 2021, authorizing a medical cannabis program similar in structure to Georgia's but with higher THC limits and more qualifying conditions. The Alabama Medical Cannabis Commission issued licenses in 2023, with the first dispensaries opening in late 2024. Alabama permits products up to 30% THC and recognizes conditions including chronic pain, PTSD, and anxiety disorders. As of May 2026, approximately 15,000 patients are registered in Alabama's program.

South Carolina: CBD-Only

South Carolina permits only CBD products derived from hemp containing less than 0.3% THC under the 2018 Farm Bill. The state has no medical cannabis program and does not recognize cannabis as medicine. Multiple legislative attempts to establish a medical program have failed in the conservative-controlled legislature. South Carolina patients with serious medical conditions often travel to neighboring states or relocate entirely to access cannabis medicine.

Tennessee: CBD-Only

Tennessee similarly permits only hemp-derived CBD products under federal law. The state legislature has repeatedly rejected medical cannabis proposals despite polling showing majority public support. Tennessee patients face the same access barriers as those in South Carolina, driving cross-border medical migration to states with legal programs.

North Carolina: Limited Research Program

North Carolina enacted limited medical cannabis legislation in 2014 permitting CBD oil for intractable epilepsy, but the program remains extremely restrictive with no in-state production or dispensaries. Patients must obtain oil from out-of-state sources. Broader medical cannabis bills have passed the North Carolina House multiple times but stalled in the Senate. As of May 2026, comprehensive medical cannabis legislation remains pending.

Market and Business Implications

Georgia's medical cannabis market remains underdeveloped compared to mature programs in other states, with estimated 2025 sales of $15-20 million constrained by limited patient enrollment, restrictive product regulations, and high operational costs. The six licensed production companies face significant financial challenges. The combination of limited patient population, 5% THC cap, and restricted product forms constrains revenue potential. Industry analysts estimate average dispensary revenue of $600,000-900,000 annually, far below the $3-5 million typical of dispensaries in comprehensive medical programs. Production costs remain high due to pharmaceutical-grade facility requirements and extensive testing mandates. Licensees report all-in production costs of $800-1,200 per liter of finished oil, compared to $300-500 per liter in states with less stringent regulations. These costs translate to retail prices of $150-200 per ounce of oil, making medicine unaffordable for many patients. The limited number of licenses creates a constrained competitive environment. With only six Class 1 producers and a maximum of 30 dispensaries permitted under current law (five per Class 1 licensee), barriers to entry remain extremely high. The 2026 legislation expanding licenses to eight total will modestly increase competition, but the market remains far from the open licensing systems in states like Oklahoma or Michigan. Multi-state operators view Georgia as a strategic foothold in the Southeast rather than a major revenue market. Trulieve's Georgia operations represent less than 2% of the company's total revenue, according to securities filings. However, the company maintains its Georgia presence anticipating future program expansion or adult-use legalization that could dramatically increase market size. Banking limitations force most Georgia dispensaries to operate cash-intensive businesses. Only a handful of small credit unions serve cannabis companies, charging premium fees for basic banking services. Most dispensaries maintain on-site safes and employ armored car services for cash transport, adding 5-10% to operational costs. Federal tax policy under Internal Revenue Code Section 280E prohibits cannabis businesses from deducting ordinary business expenses, forcing Georgia licensees to pay effective tax rates of 60-80% on gross profits. This tax treatment, combined with state-level operational costs, makes profitability extremely challenging despite limited competition. The program's economic impact on Georgia's broader economy remains modest. The six production companies employ an estimated 400-600 workers directly, with perhaps another 200-300 indirect jobs in security, testing, and professional services. State tax revenue from the program totaled approximately $2-3 million in 2025, a negligible fraction of Georgia's $30+ billion annual budget. Patient advocates argue the restrictive program design intentionally limits market development to prevent normalization of cannabis use. By maintaining tight controls and limited access, legislators signal continued skepticism about cannabis while providing minimal accommodation for patients with serious medical conditions.

What Experts Say

Medical professionals, policy analysts, and patient advocates offer divergent perspectives on Georgia's program, with physicians emphasizing the need for more clinical research, economists highlighting market inefficiencies, and patients demanding expanded access. Dr. Allen Peake, a former Georgia state representative who championed the original Haleigh's Hope Act, described the program's evolution as "frustratingly slow but moving in the right direction." In a 2025 interview with the Atlanta Journal-Constitution, Peake said the eight-year gap between legalizing possession and opening the first dispensary represented "a failure of government to serve patients who desperately needed help." He continues advocating for higher THC limits and additional qualifying conditions. Shannon Cloud, executive director of Georgia's Hope, told Georgia Public Broadcasting in April 2026 that the recent expansion adding opioid use disorder and chronic pain as qualifying conditions represents "meaningful progress, but we're still serving a fraction of the patients who could benefit from medical cannabis." Cloud emphasized that the 5% THC limit excludes many patients who require higher-potency products for effective symptom management. Dr. Anuj Mehta, a pain management specialist at Emory University Hospital, expressed cautious support for the program while noting evidence limitations. According to a 2025 interview in the Journal of the Medical Association of Georgia, Mehta said "the existing clinical literature supports cannabis efficacy for certain conditions like chemotherapy-induced nausea and neuropathic pain, but we need more rigorous research to understand optimal dosing, cannabinoid ratios, and long-term effects." He noted that the federal Schedule I classification severely restricts clinical research opportunities. From an economic perspective, Dr. Jeffrey Miron, director of economic studies at the Cato Institute, characterized Georgia's approach as "a highly regulated, artificially constrained market that generates minimal economic benefit while maintaining high barriers to patient access." In a 2024 policy brief, Miron argued that Georgia's license cap and restrictive regulations "create monopoly rents for licensees while forcing patients to pay inflated prices for limited product selection." Law enforcement perspectives remain mixed. Major William Hitchens of the Georgia State Patrol told the Georgia Recorder in 2025 that the registry system "provides a clear mechanism for officers to verify legal possession, reducing ambiguity during traffic stops and other encounters." However, he noted that the 5% THC limit creates enforcement challenges because "field testing cannot reliably distinguish compliant oil from illegal products, requiring laboratory analysis that delays prosecution decisions." Patient testimonials consistently emphasize access barriers. Jamie Essig, a registered patient with Crohn's disease, told WSB-TV in May 2026 that she drives 90 miles round-trip to the nearest dispensary and pays $180 per ounce for oil that "helps manage my symptoms but costs more than I can really afford on disability income." She said the 5% THC limit means she must consume larger volumes of oil to achieve therapeutic effects compared to higher-potency products available in other states.

What's Next: Program Evolution and Policy Outlook

Georgia's medical cannabis program faces continued expansion pressure from patient advocates, potential federal rescheduling impacts, and ongoing legislative debates over THC limits and qualifying conditions through 2026-2027. The immediate calendar includes several key decision points. The Georgia Access to Medical Cannabis Commission will accept applications for the two additional Class 1 licenses authorized in the May 2026 expansion during a 60-day window opening July 1, 2026. Industry observers expect 40-50 applications for these licenses, with awards anticipated by December 2026. The new licensees could begin operations by late 2027 or early 2028, adding up to 10 additional dispensaries. The 2027 legislative session will likely see continued expansion proposals. Patient advocacy organizations plan to push for legislation increasing the THC limit from 5% to 10% or 15%, adding additional qualifying conditions including anxiety disorders and insomnia, and permitting vaporizable products. However, these proposals face uncertain prospects in the Republican-controlled General Assembly, where many members remain skeptical of broader cannabis access. Federal policy changes could significantly impact Georgia's program. The Drug Enforcement Administration's ongoing review of cannabis scheduling, initiated by President Biden's 2022 directive, could result in rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act. Such a change would not legalize cannabis under federal law but would ease research restrictions, potentially improve banking access, and eliminate the Section 280E tax penalty for cannabis businesses. The DEA's final decision, expected in late 2026 or 2027, will shape state program economics and operations. Adult-use legalization remains a longer-term possibility. Polling conducted by the University of Georgia in 2025 showed 58% of Georgia voters support legalizing cannabis for adult use, including majorities of Democrats, independents, and voters under 50. However, Republican legislative leaders have consistently opposed adult-use legalization, and Governor Kemp has not signaled support for such a policy change. Advocates view incremental medical program expansion as the more realistic near-term path. The program's patient enrollment trajectory will influence future policy debates. If registration grows significantly following the 2026 expansion—particularly among chronic pain and opioid use disorder patients—it could build political momentum for further liberalization. Conversely, if enrollment remains modest, opponents may argue the limited demand justifies maintaining restrictive policies. Legal challenges to the program's restrictive framework remain possible. Some patient advocates have explored litigation arguing that the 5% THC limit and limited qualifying conditions violate equal protection or due process rights, though no such cases have been filed as of May 2026. The Georgia Supreme Court's general deference to legislative policy choices makes successful constitutional challenges unlikely.

Further Reading

• O.C.G.A. § 16-12-190 through § 16-12-212 (Georgia Low THC Oil Registry and Medical Cannabis statutes) - https://law.justia.com/codes/georgia/2020/title-16/chapter-12/article-4/
• Georgia Access to Medical Cannabis Commission official website - https://dph.georgia.gov/low-thc-oil-registry
• Georgia Department of Public Health Low THC Oil Registry - https://dph.georgia.gov/low-thc-oil-registry
• Georgia Composite Medical Board physician registration requirements - https://medicalboard.georgia.gov/
• House Bill 324 (2019 Georgia Access to Medical Cannabis Act) full text - http://www.legis.ga.gov/Legislation/en-US/display/20192020/HB/324
• House Bill 1 (2015 Haleigh's Hope Act) full text - http://www.legis.ga.gov/Legislation/en-US/display/20152016/HB/1
• Georgia's Hope patient advocacy organization - https://www.georgiashope.org/
• Peachtree NORML Georgia chapter - https://www.peachtreenorml.org/
• 21 U.S.C. § 812 (federal Controlled Substances Act scheduling) - https://www.law.cornell.edu/uscode/text/21/812
• Rohrabacher-Farr Amendment legislative history - https://www.congress.gov/amendment/113th-congress/house-amendment/748